Pfizer Intends to Sell Around 540 Million Ordinary Shares in Haleon
By Cristina Gallardo
Pfizer said it intends to sell around 540 million ordinary shares in British consumer-healthcare business Haleon, or about 5.9% of the company's issued share capital.
The pharmaceutical giant said Monday that the price per share will be determined by way of an accelerated bookbuilding process to institutional investors.
Pfizer will receive all net proceeds from the offering, it said.
In a separate statement, Haleon said it agreed to make an off-market purchase of approximately 230 million pounds ($307.7 million) worth of its ordinary shares from Pfizer.
Write to Cristina Gallardo at cristina.gallardo@wsj.com
(END) Dow Jones Newswires
September 30, 2024 12:28 ET (16:28 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying
-
The 10 Best Companies to Invest in Now